BMIQ12
MCID: BDY015
MIFTS: 45

Body Mass Index Quantitative Trait Locus 12 (BMIQ12)

Categories: Bone diseases, Endocrine diseases, Genetic diseases, Metabolic diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 12

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 12:

Name: Body Mass Index Quantitative Trait Locus 12 57 5 38
Obesity, Susceptibility to, Bmiq12 57 12
Obesity 57 71
Obesity, Susceptibility to 57
Obesity Bmiq12 57
Bmiq12 57

Classifications:



External Ids:

OMIM® 57 612362
UMLS 71 C0028754

Summaries for Body Mass Index Quantitative Trait Locus 12

MalaCards based summary: Body Mass Index Quantitative Trait Locus 12, also known as obesity, susceptibility to, bmiq12, is related to body mass index quantitative trait locus 11 and proprotein convertase 1/3 deficiency, and has symptoms including high weight, symptoms and obesity, metabolically benign. An important gene associated with Body Mass Index Quantitative Trait Locus 12 is PCSK1 (Proprotein Convertase Subtilisin/Kexin Type 1). The drugs Hydrocortisone and Hydrocortisone succinate have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, brain and liver.

More information from OMIM: 612362

Related Diseases for Body Mass Index Quantitative Trait Locus 12

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9 Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1 Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3 Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10 Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5 Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12 Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14 Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18 Body Mass Index Quantitative Trait Locus 19
Body Mass Index Quantitative Trait Locus 20

Diseases related to Body Mass Index Quantitative Trait Locus 12 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2465)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 11 32.3 PCSK1 LOC101929710
2 proprotein convertase 1/3 deficiency 31.6 PCSK1 LOC101929710
3 leptin deficiency or dysfunction 11.9
4 body mass index quantitative trait locus 19 11.9
5 body mass index quantitative trait locus 20 11.9
6 body mass index quantitative trait locus 8 11.9
7 body mass index quantitative trait locus 14 11.9
8 body mass index quantitative trait locus 4 11.9
9 body mass index quantitative trait locus 9 11.8
10 body mass index quantitative trait locus 18 11.8
11 body mass index quantitative trait locus 7 11.8
12 body mass index quantitative trait locus 10 11.8
13 leptin receptor deficiency 11.8
14 abdominal obesity-metabolic syndrome 1 11.6
15 obesity, early-onset, with adrenal insufficiency and red hair 11.6
16 obesity-hypoventilation syndrome 11.6
17 cohen syndrome 11.5
18 intellectual developmental disorder, x-linked, syndromic, wilson-turner type 11.5
19 abdominal obesity-metabolic syndrome 3 11.5
20 mehmo syndrome 11.5
21 abdominal obesity-metabolic syndrome 4 11.5
22 mental retardation, truncal obesity, retinal dystrophy, and micropenis syndrome 11.5
23 morbid obesity and spermatogenic failure 11.5
24 momo syndrome 11.4
25 type 2 diabetes mellitus 11.4
26 chops syndrome 11.4
27 abdominal obesity-metabolic syndrome quantitative trait locus 2 11.4
28 spastic paraplegia, intellectual disability, nystagmus, and obesity 11.4
29 coenzyme q10 deficiency, primary, 2 11.4
30 obesity, hyperphagia, and developmental delay 11.4
31 retinal dystrophy and obesity 11.3
32 non-alcoholic fatty liver disease 11.3
33 hypothalamic obesity 11.3
34 hydrocephalus obesity hypogonadism 11.3
35 fatty liver disease 11.3
36 obesity due to sim1 deficiency 11.3
37 chung-jansen syndrome 11.3
38 coloboma-obesity-hypogenitalism-mental retardation syndrome 11.3
39 aniridia - ptosis - intellectual disability - familial obesity 11.3
40 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 11.3
41 prader-willi syndrome 11.3
42 prediabetes syndrome 11.3
43 severe early-onset obesity-insulin resistance syndrome due to sh2b1 deficiency 11.3
44 camera-marugo-cohen syndrome 11.2
45 wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome 11.2
46 mental retardation, obesity, mandibular prognathism, and eye and skin anomalies 11.2
47 phip-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome 11.2
48 ayazi syndrome 11.2
49 glucose intolerance 11.2
50 man1b1-cdg 11.2

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 12:



Diseases related to Body Mass Index Quantitative Trait Locus 12

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 12

Clinical features from OMIM®:

612362 (Updated 24-Oct-2022)

UMLS symptoms related to Body Mass Index Quantitative Trait Locus 12:


high weight; symptoms; obesity, metabolically benign; monogenic obesity

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 12

Drugs for Body Mass Index Quantitative Trait Locus 12 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 942)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
2
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
3
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
4
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
5
Lactitol Approved, Investigational Phase 4 585-86-4, 585-88-6 157355 493591
6
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
7
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
8
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6 9578005
9
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
10
Indapamide Approved Phase 4 26807-65-8 3702
11
Insulin aspart Approved Phase 4 116094-23-6 16132418
12
Tolnaftate Approved, Investigational, Vet_approved Phase 4 2398-96-1 5510
13
Erythromycin Approved, Investigational, Vet_approved Phase 4 55-31-2, 114-07-8 12560
14
Insulin lispro Approved Phase 4 133107-64-9 16132438
15
Hydroxychloroquine Approved Phase 4 118-42-3 3652
16
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
17
Cyproterone acetate Approved, Investigational Phase 4 427-51-0 9880
18
Phentermine Approved, Illicit Phase 4 122-09-8 4771
19
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
20
Losartan Approved Phase 4 114798-26-4 3961
21
Rosiglitazone Approved, Investigational Phase 4 122320-73-4, 155141-29-0 77999
22
Coal tar Approved Phase 4 8007-45-2
23 Tomato Approved Phase 4
24
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
25
Epitestosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 5408 10204 6013
26
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
27
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
28
Loperamide Approved Phase 4 53179-11-6 3955
29
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
30
Calcium carbonate Approved, Investigational Phase 4 471-34-1
31
Tocopherol Approved, Investigational Phase 4 1406-66-2
32
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
33
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
34
Polyestradiol phosphate Approved Phase 4 28014-46-2
35
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
36 Orange Approved Phase 4
37
Acetaminophen Approved Phase 4 103-90-2 1983
38
Infliximab Approved Phase 4 170277-31-3
39
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
40
Apixaban Approved Phase 4 503612-47-3 10182969
41
Ethinylestradiol Approved Phase 4 57-63-6 5991
42
Drospirenone Approved Phase 4 67392-87-4 68873
43
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
44
Fenofibrate Approved Phase 4 49562-28-9 3339
45
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
46
Moxifloxacin Approved, Investigational Phase 4 186826-86-8, 354812-41-2, 151096-09-2 152946
47
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
48
Atorvastatin Approved Phase 4 134523-00-5 60823
49
Glyburide Approved Phase 4 10238-21-8 3488
50
Desflurane Approved Phase 4 57041-67-5 42113

Interventional clinical trials:

(show top 50) (show all 8889)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Effects of Laying Early (Between 12 and 16) a Gastric Band on the Prevention of Morbid Obesity in Late Adolescence. Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
2 Prevention and Control of Obesity in Primary School Children in Tehran Unknown status NCT02082080 Phase 4
3 A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity. Unknown status NCT01864187 Phase 4 Dexmedetomidine
4 The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial Unknown status NCT01360710 Phase 4 Moxonidine;Irbesartan
5 Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control :A Randomized, Open, Controlled and Single-site Clinical Trail Unknown status NCT03593668 Phase 4 Metformin;Benaglutide
6 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
7 Treatment of Obesity With Topiramate in Patients With Polycystic Ovary Syndrome: a Double-blind Placebo-controlled Clinical Trial Unknown status NCT04453306 Phase 4 Topiramate;Placebo
8 The Effect of Obesity in Dexmedetomidine Metabolic Clearance Unknown status NCT02557867 Phase 4 Dexmedetomidine
9 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
10 Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
11 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
12 Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
13 The Therapeutic Effect of Catgut Embedding in Obesity-A Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02276235 Phase 4
14 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
15 Preoperative Carbohydrate Loading in Bariatric Surgery - Randomized Clinical Trail Unknown status NCT04486079 Phase 4
16 Laparoscopic Non Banded Vertical (Magenstrasse and Mill) Gastroplasty In Bariatric Surgery. Morbidity and Results on Weight Loss and Associated Co-morbidities Unknown status NCT02050477 Phase 4
17 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
18 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
19 Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial Unknown status NCT02017314 Phase 4 Morphine
20 Effect of POSTbiotics Supplementation on Microbiome in OBese Children: the POST-OB Study Unknown status NCT04151823 Phase 4 Vitamin D3;Immunofos
21 Could Gut Microbiome Contribute to the Therapeutic Effect of Liraglutide 3.0 mg? A Randomized Double Blind Placebo Controlled Trial Unknown status NCT04046822 Phase 4 Liraglutide 6 MG/ML [Saxenda];Placebo
22 International, Multi Centre, Open, Prospective, Randomized Study: Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
23 Comparing the Efficacy of Two Frequently Used Doses of Enoxaparin for VTE Prophylaxis After Bariatric Surgery Unknown status NCT01970202 Phase 4 40mg Enoxaparin;60mg Enoxaparin
24 Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial Unknown status NCT00327912 Phase 4
25 Laparoscopic Bariatric Surgery: Impact of the Level of Neuromuscular Blockade on Surgical Conditions - Comparison Between Moderate and Deep Neuromuscular Blockade Unknown status NCT02118844 Phase 4 rocuronium
26 Levonorgestrel-releasing Intrauterine Device Effects on Hemostatic and Arterial Function of Obese Women Unknown status NCT01320917 Phase 4
27 Prospective Randomized Study of Effects of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
28 Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project Unknown status NCT01015599 Phase 4
29 Prospective, Pharmacokinetic Study for Determination of the Relationship Between Lean Body Weight and Anti-Xa Activity 4 Hours After Subcutaneous Injection of 5700 IU Nadroparin in Morbidly Obese Patients After Bariatric Surgery. Unknown status NCT02295150 Phase 4 Nadroparin
30 Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass Unknown status NCT02374632 Phase 4
31 Effect of Daily Glucomannan in Overweight Patients Unknown status NCT01485718 Phase 4
32 The Effect of Weight Loss With Orlistat or Sibutramine Administration , Hypocaloric Diet and Physical Exercise , on AMH Levels, in Women With Polycystic Ovary Syndrome Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
33 Beijing Chao-yang Hospital, Capital Medical University Unknown status NCT02583438 Phase 4 Saxagliptin (Bristol-Myers Squibb Company)
34 Investigating Whether the Magnitude of Postoperative Inflammatory and Insulin Resistant Responses is Related to Body Composition and Physiological Function of Skeletal Muscle & Adipose Tissue Unknown status NCT01470534 Phase 4
35 The Effect of Mirabegron on Brown Adipose Tissue in Healthy Young White Caucasian and South Asian Men Unknown status NCT03012113 Phase 4 Mirabegron;Placebo Oral Capsule
36 A 24-Week, National, Single-Centre, Open-Labelled, Randomised, Parallel-Group Trial Comparing Energy Expenditure With Insulin Detemir Versus NPH Insulin Using a Basal-Bolus Regimen With Insulin Aspart as the Mealtime Insulin in Subjects With Type 2 Diabetes Unknown status NCT00788840 Phase 4 Insulatard;Detemir
37 The Use of Antimicrobial Gauze in Pregnant Women Undergoing C-section With BMI >40 to Decrease Wound Complications by 6 Weeks postpartum--a Small Feasibility Study Unknown status NCT02882360 Phase 4
38 Influence of Erythromycin on ad Libitum Food Intake and the Evaluation of Motilin in Food Timing in Healthy Volunteers and Patients Unknown status NCT03024879 Phase 4 Erythromycin;Saline
39 The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men Unknown status NCT03002675 Phase 4 Bydureon
40 Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity) Unknown status NCT02055014 Phase 4 Liraglutide
41 HYpertension Therapy With Valsartan Versus EpleRenone for Obese Patients: A Randomized Clinical Trial Unknown status NCT03476616 Phase 4 Eplerenone (-based therapy) arm;Valsartan (-based therapy) arm
42 Synergy Effect of the Appetite Hormone GLP-1 (LiragluTide) and Exercise on Maintenance of Weight Loss and Health After a Low Calorie Diet - the S-LiTE Randomized Trial Unknown status NCT04122716 Phase 4 Liraglutide
43 The Effect of Liraglutide on MMC Activity, Gastrointestinal Hormones, Hunger Ratings and ad Libitum Food Intake in Healthy Volunteers Unknown status NCT04008290 Phase 4 0.6 mg Liraglutide;Placebo
44 The Efficacy of a Once Weekly Glucagon-Like Peptide-1 Agonist on Body Weight/Composition and Metabolic Parameters in Persons With SCI Unknown status NCT03292315 Phase 4 Exenatide 2 MG Injection [Bydureon]
45 A Pilot Study: Comparing Physiological Parameters and Outcome Variables Using Pressure Support Ventilation Versus Pressure Controlled Ventilation in Patients With Chronic Respiratory Failure Unknown status NCT00994552 Phase 4
46 Metformin Treatment for Preventing Gestational Diabetes in High-risk Patients Unknown status NCT00883259 Phase 4 Metformin
47 Effects of Valsartan on Metabolic Syndrome in Patients With Hypertension Unknown status NCT00790946 Phase 4 Valsartan
48 Efficacy and Safety of Liraglutide-bolus (Liraglutide Plus Prandial Insulin) Versus Glargine-bolus Therapy in Overweight / Obese Patients With Uncontrolled Type 2 Diabetes (LiraGooD)--A Multicenter Randomized Controlled Study Unknown status NCT03087032 Phase 4 Liraglutide;insulin glargine
49 Vitamin D Concentrations and Their Effect on Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
50 Study of Metabolic Effects of EndoBarrier Versus Intragastric Balloon in Obese Patients With Type 2 Diabetes. Unknown status NCT01848795 Phase 4

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 12

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Benzphetamine
Benzphetamine hydrochloride
Dexfenfluramine
Dexfenfluramine Hydrochloride
Diethylpropion
Diethylpropion Hydrochloride
Fenfluramine
Fenfluramine Hydrochloride
lorcaserin
lorcaserin hydrochloride
Mazindol
Methamphetamine
orlistat
phendimetrazine
PHENDIMETRAZINE HYDROCHLORIDE
phendimetrazine tartrate
Phenmetrazine
Phenmetrazine Hydrochloride
Phentermine
Phentermine Hydrochloride
PHENTERMINE RESIN
Phenylpropanolamine
Phenylpropanolamine Hydrochloride
sibutramine
SIBUTRAMINE HYDROCHLORIDE

Genetic Tests for Body Mass Index Quantitative Trait Locus 12

Anatomical Context for Body Mass Index Quantitative Trait Locus 12

Organs/tissues related to Body Mass Index Quantitative Trait Locus 12:

MalaCards : Skeletal Muscle, Brain, Liver, Adipocyte, Heart, Breast, Endothelial

Publications for Body Mass Index Quantitative Trait Locus 12

Articles related to Body Mass Index Quantitative Trait Locus 12:

(show top 50) (show all 30004)
# Title Authors PMID Year
1
Common nonsynonymous variants in PCSK1 confer risk of obesity. 62 57 5
18604207 2008
2
Genome-wide linkage analysis for severe obesity in french caucasians finds significant susceptibility locus on chromosome 19q. 62 57
15220211 2004
3
A genome-wide scan for human obesity genes reveals a major susceptibility locus on chromosome 10. 62 57
9806554 1998
4
A genome-wide scan for quantitative trait loci linked to obesity phenotypes among West Africans. 57
15611782 2005
5
Genomic scan for genes affecting body composition before and after training in Caucasians from HERITAGE. 57
11299268 2001
6
Changes in obesity and iron deficiency between 4 and 9 years of age. Longitudinal study of childhood obesity (ELOIN). 62
35931811 2022
7
Sarcopenic Obesity Is Associated With Reduced Cardiorespiratory Fitness Compared With Nonsarcopenic Obesity in Patients With Heart Failure With Reduced Ejection Fraction. 62
36098058 2022
8
Addiction-like behaviour towards high-fat high-sugar food predicts relapse propensity in both obesity prone and obesity resistant C57BL/6 J mice. 62
36209772 2022
9
Trends in Obesity Prevalence Among Patients Enrolled in Clinical Trials for Obesity-Related Cancers, 1986 to 2016. 62
36215073 2022
10
Potential novel biomarkers in small intestine for obesity/obesity resistance revealed by multi-omics analysis. 62
36209126 2022
11
Obesity and "obesity-related" cancers: are there body mass index cut-points? 62
35817851 2022
12
Possible mediators of metabolic endotoxemia in women with obesity and women with obesity-diabetes in The Gambia. 62
35933445 2022
13
Association of environmental exposure to perchlorate, nitrate, and thiocyanate with overweight/obesity and central obesity among children and adolescents in the United States of America using data from the National Health and Nutrition Examination Survey (NHANES) 2005-2016. 62
36251327 2022
14
Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society. 62
36268562 2022
15
The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits. 62
35902734 2022
16
Butyrate to combat obesity and obesity-associated metabolic disorders: Current status and future implications for therapeutic use. 62
35856338 2022
17
The prevalence of general obesity, abdominal obesity, and hypertension and its related risk factors among young adult students in Bangladesh. 62
36000198 2022
18
The influence of BMI in asthma. Which traits are due to obesity and which to asthma and obesity phenotype? 62
36200980 2022
19
Evaluating anti-obesity potential, active components, and antioxidant mechanisms of Moringa peregrina seeds extract on high-fat diet-induced obesity. 62
35661366 2022
20
The impact of obesity on the outcome of severe SARS-CoV-2 ARDS in a high volume ECMO centre: ECMO and corticosteroids support the obesity paradox. 62
36219946 2022
21
Obesity and Eligibility for Obesity Treatments Among Adults With Disabilities in the U.S. 62
35613976 2022
22
Enrolling Caregivers in Obesity Interventions to Improve Obesity-Related Outcomes in Children. 62
34353179 2022
23
Microbiota modulation and anti-obesity effects of fermented Pyrus ussuriensis Maxim extract against high-fat diet-induced obesity in rats. 62
36058150 2022
24
Support needs of people living with obesity during transition from tertiary obesity treatment to community care. 62
36207249 2022
25
Letter to the Editor re: Patient-Centered Care for Obesity: How We Can Treat Obesity While Actively Fighting Weight Stigma and Eating Disorder Risk. 62
36206862 2022
26
Fatty Liver/Adipose Tissue Dual-Targeting Nanoparticles with Heme Oxygenase-1 Inducer for Amelioration of Obesity, Obesity-Induced Type 2 Diabetes, and Steatohepatitis. 62
36209391 2022
27
Eight-year trends in obesity-related complications and healthcare cost progression in a US population with obesity: a retrospective cohort study. 62
36263756 2022
28
Modeling Obesity-Driven Pancreatic Carcinogenesis-A Review of Current In Vivo and In Vitro Models of Obesity and Pancreatic Carcinogenesis. 62
36231132 2022
29
Intentional weight loss reduces cancer risk and mortality: New studies suggest that bariatric surgery can make a difference in risk and mortality reduction for obesity-related cancer types: New studies suggest that bariatric surgery can make a difference in risk and mortality reduction for obesity-related cancer types. 62
36161430 2022
30
The energy balance hypothesis of obesity: do the laws of thermodynamics explain excessive adiposity? 62
34983955 2022
31
Metabolically healthy and unhealthy obesity and risk of vasomotor symptoms in premenopausal women: cross-sectional and cohort studies. 62
35596933 2022
32
Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling. 62
35217813 2022
33
Obesity, Hypovitaminosis D, and COVID-19: the Bermuda Triangle in Public Health. 62
35391661 2022
34
The COVID-19, Obesity, and Food Insecurity Syndemic. 62
35138590 2022
35
Meal occasion, overweight, obesity and central obesity in children and adults: a cross-sectional study based on a nationally representative survey. Colombia, 2015. 62
36123072 2022
36
Famine exposure in adolescence is associated with a higher risk of overweight/obesity and abdominal obesity in adulthood: A meta-analysis. 62
36215886 2022
37
Changes in Novel Anthropometric Indices of Abdominal Obesity during Weight Loss with Selected Obesity-Associated Single-Nucleotide Polymorphisms: A Small One-Year Pilot Study. 62
36142109 2022
38
The Leading Factors of Obesity and Severe Obesity in Korean Adults during the COVID-19 Pandemic. 62
36231516 2022
39
The use of virtual visits for obesity pharmacotherapy in patients with overweight or obesity compared with in-person encounters. 62
36156456 2022
40
Comparison of distal primary obesity surgery endolumenal techniques for the treatment of obesity (with videos). 62
35568242 2022
41
Maternal High-Fat Diet Programs White and Brown Adipose Tissues In Vivo in Mice, with Different Metabolic and Microbiota Patterns in Obesity-Susceptible or Obesity-Resistant Offspring. 62
36144232 2022
42
Factors of Obesity and Metabolically Healthy Obesity in Asia. 62
36143948 2022
43
Metabolically healthy obesity in a paediatric obesity clinic. 62
35993884 2022
44
Association between obesity and atopic dermatitis in children: A case-control study in a high obesity prevalence population. 62
36047809 2022
45
Using Economics to Impact Local Obesity Policy: Introducing the UK Centre for Economics of Obesity (CEO). 62
35723837 2022
46
The effects of chitosan supplementation on anthropometric indicators of obesity, lipid and glycemic profiles, and appetite-regulated hormones in adolescents with overweight or obesity: a randomized, double-blind clinical trial. 62
36064382 2022
47
Health consequences of obesity and projected future obesity health burden in China. 62
36000246 2022
48
Factors associated with the perception of parents and children regarding obesity-related terminology used by healthcare professionals in a sample of Korean children and adolescents with obesity. 62
35989180 2022
49
The Australian Obesity Management Algorithm: A simple tool to guide the management of obesity in primary care. 62
36050266 2022
50
Prenatal Metabolomic Profiles Mediate the Effect of Maternal Obesity On Early Childhood Growth Trajectories and Obesity Risk: the CANDLE Study. 62
36055779 2022

Variations for Body Mass Index Quantitative Trait Locus 12

ClinVar genetic disease variations for Body Mass Index Quantitative Trait Locus 12:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PCSK1, LOC101929710 NM_000439.5(PCSK1):c.661A>G (p.Asn221Asp) SNV Risk Factor
14040 rs6232 GRCh37: 5:95751785-95751785
GRCh38: 5:96416081-96416081

Expression for Body Mass Index Quantitative Trait Locus 12

Search GEO for disease gene expression data for Body Mass Index Quantitative Trait Locus 12.

Pathways for Body Mass Index Quantitative Trait Locus 12

GO Terms for Body Mass Index Quantitative Trait Locus 12

Sources for Body Mass Index Quantitative Trait Locus 12

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....